As it is hypothesized SPARC3+ COL3A1+ fibroblast remodel the synovial vasculature to facilitate immune cell infiltration in early disease, it is probable NOTCH3 therapy could be more effective when employed in undifferentiated or very early RA cohorts. Here, COL3A1 is linked to rheumatoid arthritis.